You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):SHR8028滴眼液獲批開展治療乾眼病臨牀試驗

格隆匯3月28日丨恆瑞醫藥(600276.SH)公佈,近日,公司子公司成都盛迪醫藥有限公司收到國家藥監局核准簽發關於SHR8028滴眼液的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。經審查,2021年12月31日受理的SHR8028滴眼液符合藥品註冊的有關要求,同意本品開展治療乾眼病的臨牀試驗。

SHR8028滴眼液是公司從Novaliq公司引進的CyclASol(1%環孢菌素A製劑),SHR8028滴眼液是一種抗炎和免疫調節劑,用於乾眼症的治療,目前正在美國進行Ⅲ期臨牀試驗。經查詢,目前用於治療乾眼症的環孢素A滴眼液中,美國已上市的產品包括艾爾建的Restasis(0.05%,乳劑)和太陽製藥的Cequa(0.09%,納米膠束水溶液);歐洲已上市的產品包括參天製藥的Ikervis(0.1%,陽離子納米乳劑);韓國已上市的產品包括Cyporin(0.05%,納米水溶液)。國內興齊眼藥3類仿製藥環孢素滴眼液(II)於2020年6月獲國家藥監局批准上市。

經查詢,2020年Restasis、Cequa、Ikervis、Cyporin及興齊眼藥環孢素滴眼液全球銷售額合計約為21.29億美元。截至目前,SHR8028滴眼液相關項目累計已投入研發費用約7011萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account